SCHEMBL30325923

SCHEMBL30325923

C=C(F)C(=O)Nc1ccc(-c2nn3ncnc(N)c3c2-c2ccc(C(=O)NCC(F)F)c(OC)c2)c(OC)c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.35
▸ BTK Q06187 7/20 0.34
▸ EGFR P00533 4/20 0.34
▸ CSNK2A2 P19784 1/20 0.33
▸ CSNK2A1 P68400 1/20 0.33
▸ MCHR1 Q99705 3/20 0.33
▸ EIF2S1 P05198 1/20 0.33
▸ EIF2AK3 Q9NZJ5 1/20 0.33
▸ FGFR1 P11362 1/20 0.32
▸ KIT P10721 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ TNK2 Q07912 1/20 0.32
▸ TEC P42680 2/20 0.32
▸ TXK P42681 2/20 0.32
▸ BMX P51813 2/20 0.32
▸ RIPK1 Q13546 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325959 0.95 BTK (0.34) PIK3CDBTKEGFRCSNK2A2CSNK2A1
SCHEMBL30326048 0.93 BTK (0.37) PIK3CDBTKEGFRCSNK2A2CSNK2A1
SCHEMBL30325702 0.90 BTK (0.36) BTKEGFRCSNK2A2CSNK2A1MCHR1
SCHEMBL30326063 0.89 BTK (0.34) BTKEGFRCSNK2A2CSNK2A1MCHR1
SCHEMBL30325951 0.87 CSNK2A2 (0.47) BTKCSNK2A2CSNK2A1MCHR1TNK2
SCHEMBL30325631 0.86 TNK2 (0.35) BTKEGFRCSNK2A2CSNK2A1EIF2S1
SCHEMBL30325666 0.85 TNK2 (0.36) BTKEGFRCSNK2A2CSNK2A1EIF2S1
SCHEMBL30326043 0.85 CSNK2A2 (0.34) BTKEGFRCSNK2A2CSNK2A1EIF2S1
SCHEMBL30326023 0.85 BTK (0.35) BTKEGFRCSNK2A2CSNK2A1EIF2AK3
SCHEMBL30325957 0.85 FGFR1 (0.41) PIK3CDBTKEGFRCSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 PIK3CD 889/4885BTK 168/4885EGFR 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback